← All Aim Immunotech INC filings

Aim Immunotech INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
AIM
Aim Immunotech INC
10-K: AIM ImmunoTech Faces Delisting Risk Amidst Pancreatic Cancer Focus
AIM ImmunoTech's 2025 annual report highlights a strategic pivot to late-stage pancreatic cancer for Ampligen, despite ongoing financial losses and NYSE American delisting concerns.
AMEX
AIM
Aim Immunotech INC
10-K: AIM ImmunoTech Reports Annual Results, Faces Going Concern Uncertainty and Potential NYSE American Delisting
AIM ImmunoTech reports a reduced net loss for 2024 but faces substantial doubt about its ability to continue as a going concern and potential delisting from the NYSE American due to stockholders' equity deficiency.
AMEX
AIM
Aim Immunotech INC
10-K: AIM ImmunoTech Details Common Stock Structure and Anti-Takeover Measures in 10-K Filing
AIM ImmunoTech's 10-K filing outlines the characteristics of its common stock, including voting, dividend, and liquidation rights, as well as anti-takeover provisions.